FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歸創通橋醫療科技股份有限公司 呈交日期： 2025年9月18日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02190 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | ...

Core Viewpoint - The Chinese innovative drug industry is gradually catching up with Europe and the United States in terms of technology, with some targets and technical pathways already leading globally. The number and value of new drugs authorized for overseas markets continue to increase, leading to world-class pricing and non-linear investment elasticity. The domestic market is experiencing strong growth in demand, with domestic new drug sales continuing to rise, and several innovative pharmaceutical companies have turned losses into profits, entering a stable growth phase [2]. Group 1: Innovative Drugs - The innovative drug sector is witnessing a significant increase in sales driven by strong domestic demand, with a number of innovative companies achieving profitability [2]. - The trend of domestic innovative drugs going overseas is accelerating, with increasing numbers and values of new drug authorizations [2]. - The industry is positioned for a "Davis double" effect, where both performance and valuation are expected to improve [2]. Group 2: High-Value Medical Consumables - The orthopedic sector is expected to see mild price reductions, while domestic replacements continue to grow, and overseas business progresses rapidly [2]. - The neurosurgery and neurointervention fields are stabilizing after centralized procurement, with new products expected to contribute to growth [2]. Group 3: Medical Devices - The medical device sector is experiencing a high-speed growth in bidding data, with companies entering a destocking phase, which is expected to improve performance in the second half of the year [2]. - The low-value consumables sector is seeing continuous product upgrades and accelerated expansion into overseas markets [2]. Group 4: Blood Products - The supply side of the blood products industry is increasingly concentrated among state-owned enterprises, leading to a clearer competitive landscape [2]. - The demand side is expected to upgrade towards new products, gradually improving the industry's overall health [2]. Group 5: API (Active Pharmaceutical Ingredients) - The industry is at an upward turning point due to the end of a capital expenditure peak, combined with three growth drivers: new high-end market products, integrated consolidation and overseas expansion, and cost-leading CDMO [2]. - Leading companies are expected to see explosive growth in revenue and profits in the medium term [2]. Group 6: CXO (Contract Research Organization) - The CXO sector is seeing a revival in A+H financing activity, with multiple significant business developments enhancing market confidence [2]. - The focus is on optimizing the supply-side landscape and increasing market share for leading CRO companies [2]. Group 7: Traditional Chinese Medicine and Retail Pharmacy - The traditional Chinese medicine sector is showing signs of recovery, with friendly pricing for new drugs, while the retail pharmacy sector is influenced by supply-side adjustments and business model upgrades [2]. - The performance of offline pharmacies is expected to improve in the second half of 2025, with leading chains like YaoXingTang making progress in store upgrades [2]. Group 8: Research Reports - A series of in-depth research reports on various companies and sectors within the pharmaceutical and medical device industries have been published, highlighting their growth potential and market positioning [3][4].

Summary of Key Points Core Viewpoint - On September 17, 28 Hong Kong-listed companies conducted share buybacks, totaling 16.7684 million shares and an aggregate amount of HKD 649 million [1][2]. Group 1: Share Buyback Details - Tencent Holdings repurchased 839,000 shares for HKD 551 million, with a highest price of HKD 663.50 and a lowest price of HKD 645.50, bringing its total buyback amount for the year to HKD 52.707 billion [1][2]. - Hang Seng Bank repurchased 200,000 shares for HKD 23.8014 million, with a highest price of HKD 119.30 and a lowest price of HKD 118.40, totaling HKD 793 million in buybacks for the year [1][2]. - Pacific Shipping repurchased 6 million shares for HKD 14.9526 million, with a highest price of HKD 2.52 and a lowest price of HKD 2.45, accumulating HKD 203 million in buybacks for the year [1][2]. Group 2: Ranking of Buybacks - The highest buyback amount on September 17 was from Tencent Holdings at HKD 551 million, followed by Hang Seng Bank at HKD 23.8014 million [1][2]. - In terms of share quantity, Pacific Shipping led with 6 million shares repurchased, followed by Linklogis Technology and Weigao Group with 2.3 million and 1.9548 million shares, respectively [1][2]. Group 3: Additional Buyback Information - Other notable companies involved in buybacks include Weigao Group, MGM China, and Jitu Express, with respective buyback amounts of HKD 11.4255 million, HKD 7.873 million, and HKD 7.8348 million [2][3]. - The buyback activity reflects a strategic move by these companies to enhance shareholder value amid market conditions [1][2].

Summary of Key Points Core Viewpoint - Multiple companies, including Tencent Holdings and Hang Seng Bank, conducted share buybacks on September 17, 2025, with Tencent leading in both the number of shares repurchased and the total amount spent. Group 1: Company Buyback Details - Tencent Holdings (00700) repurchased 839,000 shares for a total of 551 million, with a year-to-date total of 58.158 million shares, representing 0.633% of its total share capital [1][2] - Hang Seng Bank (00011) repurchased 200,000 shares for 23.8014 million, with a year-to-date total of 6.93 million shares, representing 0.368% of its total share capital [2] - Pacific Shipping (02343) repurchased 6 million shares for 14.9526 million, with a year-to-date total of 41.006 million shares, representing 0.798% of its total share capital [2] - Weigao Group (01066) repurchased 1.9548 million shares for 11.4255 million, with a year-to-date total of 14.2136 million shares, representing 3.148% of its total share capital [2] - MGM China (02282) repurchased 502,000 shares for 7.873 million, with a year-to-date total of 2.23295 million shares, representing 0.587% of its total share capital [2] Group 2: Other Notable Buybacks - Jitu Express-W (01519) repurchased 870,000 shares for 7.8348 million, with a year-to-date total of 870,000 shares, representing 0.010% of its total share capital [2] - Linkage Technology-W (09959) repurchased 2.3 million shares for 7.4586 million, with a year-to-date total of 19.9075 million shares, representing 0.932% of its total share capital [2] - Mengniu Dairy (02319) repurchased 200,000 shares for 3.074 million, with a year-to-date total of 10.816 million shares, representing 0.276% of its total share capital [2] - China Hongqiao (01378) repurchased 112,500 shares for 2.822 million, with a year-to-date total of 150 million shares, representing 1.610% of its total share capital [2] - Coolpad Group (02369) repurchased 1.348 million shares for 1.8057 million, with a year-to-date total of 23.095 million shares, representing 5.639% of its total share capital [2]

智通财经APP讯，归创通桥(02190)公布，2025年9月17日耗资124.396万港元回购5万股股份。 ...

格隆汇9月17日丨归创通桥(02190.HK)公告，9月17日耗资124.4万港元回购5万股。 ...

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 呈交日期： 2025年9月17日 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 公司名稱： 歸創通橋醫療科技股份有限公司 表格類別： 股票 狀態： 新提交 (註7) | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02190 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 ...

格隆汇9月16日丨归创通桥(02190.HK)公告，9月16日耗资125.3万港元回购5万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歸創通橋醫療科技股份有限公司 呈交日期： 2025年9月16日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02190 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | ...

格隆汇9月15日丨归创通桥(02190.HK)公告，9月15日耗资129.2万港元回购5万股，每股回购价25.58- 26.14港元。 ...